Diabetes and oral therapies: A review of oral therapies for diabetes mellitus

Journal of Taibah University Medical Sciences

Volumn 11, Issue 4, 2016, Pages 317-329

  Alhadramy, Mohamad S ^a  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

Author keywords

Cardiovascular events; Drug safety; Glycaemic management; Hypoglycaemic agent; New antidiabetic therapy

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA;

ANTIDIABETIC ACTIVITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; LACTIC ACIDOSIS; MONOTHERAPY; PATIENT PREFERENCE; REVIEW;

EID: 84963652792     PISSN: 16583612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtumed.2016.02.001     Document Type: Review

References (120)

1. 1 Wermuth, Camille G., (eds.) The practice of medicinal chemistry, 2008, Elsevier Ltd.
2. 2 Patade, G.R., Marita, A.R., Metformin: a journey from countryside to the bedside. J Obes Metab Res 1 (2014), 127–130.
3. 3 Williams, R.H., Palmer, J.P., Farewell to phenformin for treating diabetes mellitus. Ann Intern Med 83 (1975), 567–568.
4. 4 Hundal, R.S., Krssak, M., Dufour, S., Laurent, D., Lebon, V., Chandramouli, V., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 (2000), 2063–2069.
5. 5 Pernicova, I., Korbonits, M., Metformin – mode of action and clinical implications for diabetes mellitus and cancer. Nat Rev Endocrinol 10 (2014), 143–156.
6. 6 Chia, C.W., Egan, J.M., Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93 (2008), 3703–3716.
7. 7 Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
8. 8 Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A.W., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
9. 9 [No authors listed], Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 12:352 (1998), 854–865.
10. 10 Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.C., Marinopoulos, S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007), 386–399.
11. 11 Inzucchi, S.E., Oral antihyperglycemic therapy for type 2 diabetes scientific review. J Am Med Assoc 287 (2002), 360–372.
12. 12 Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Nigel, P., Jones, N.P., et al., For the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006), 2427–2443.
13. 13 Berkowitz, S.A., Krumme, A.A., Avorn, J., Brennan, T., Matlin, O.S., Spettell, C.M., et al. Initial choice of oral glucose-lowering medication for diabetes mellitus. A patient-centered comparative effectiveness study. JAMA Intern Med 174 (2014), 1955–1962.
14. 14 Cubeddu, L.X., Bönisch, H., Göthert, M., Molderings, G., Racké, K., Ramadori, G., et al. Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol 361 (2000), 85–91.
15. 15 Ali, S., Fonseca, V., Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother 13 (2012), 1797–1805.
16. 16 Sánchez, H., Masferrer, D., Lera, L., Arancibia, E., Angel, B., Albala, C., Vitamin B12 deficiency associated with high doses of metformin in older people diabetic. Nutr Hosp 29 (2014), 1394–1400.
17. 17 Salpeter, S.R., Greyber, E., Pasternak, G.A., Salpeter, E.E., Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 14, 2010, CD002967.
18. 18 Eurich, D.T., Weir, D.L., Majumdar, S.R., Tsuyuki, R.T., Johnson, J.A., Lisa Tjosvold, L., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure systematic review of observational studies involving 34 000 patients. Circ Heart Fail 6 (2013), 395–402.
19. 19 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0569d5d5-70df-46d7-954a-fe00542a7191 [accessed 27.01.16].
20. 20 Ekström, N., Schiöler, L., Svensson, A., Eeg-Olofsson, K., Junmei Jonasson, J.M., Zethelius, B., et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open, 2, 2012, e001076.
21. 21 http://www.acr.org/∼/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf/#page=37 [accessed 27.01.16].
22. 22 Henquin, J.C., The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?. Diabetologia 35 (1992), 907–912.
23. 23 Groop, L.C., Ratheiser, K., Luzi, L., Melander, A., Simonson, D.C., Petrides, A., et al. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study. Acta Diabetol 28 (1991), 162–168.
24. 24 UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
25. 25 Tolman, K.G., Fonseca, V., Dalpiaz, A., Tan, M.H., Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30 (2007), 734–743.
26. 26 Brackett, C.C., Sulfonamide allergy and cross-reactivity. Curr Allergy Asthma Rep 7 (2007), 41–48.
27. 27 Nissen, S.E., Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med 157 (2012), 671–672.
28. 28 Goldner, M.G., Knatterud, G.L., Prout, T.E., Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III. Clinical implications UGDP results. J Am Med Assoc 218 (1971), 1400–1410.
29. 29 Evans, J.M., Ogston, S.A., Emslie-Smith, A., Morris, A.D., Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (2006), 930–936.
30. 30 Roumie, C.L., Hung, A.M., Greevy, R.A., Grijalva, C.G., Liu, X., Murff, H.J., et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Ann Intern Med 157 (2012), 601–610.
31. 31 Simpson, S.H., Majumdar, S.R., Tsuyuki, R.T., Eurich, D.T., Johnson, J.A., Dose–response relation between sulfonylurea drugs and mortality in type2 diabetes mellitus: a population-based cohort study. CMAJ 174 (2006), 169–174.
32. 32 Advance Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
33. 33 Stenman, S., Melander, A., Groop, P., Groop, L.C., What is the benefit of increasing the sulfonylurea dose?. Ann Intern Med 118 (1993), 169–172.
34. 34 Rodbard, H.W., Jellinger, P.S., Davidson, J.A., Einhorn, D., Garber, A.J., George Grunberger, G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15 (2009), 540–559.
35. 35 Harrower, A.D., Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31 (1996), 111–119.
36. 36 Holstein, A., Plaschke, A., Hammer, C., Egberts, E.H., Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 59 (2003), 91–97.
37. 37 National Kidney Foundation, KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60 (2012), 850–886.
38. 38 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [accessed 11, 2015].
39. 39 Fuhlendorff, J., Rorsman, P., Kofod, H., Brand, C.L., et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47 (1998), 345–351.
40. 40 Dornhorst, A., Insulinotropic meglitinide analogues. Lancet 358 (2001), 1709–1716.
41. 41 Owens, D.R., Luzio, S.D., Ismail, I., Bayer, T., Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 23 (2000), 518–523.
42. 42 Moses, R.G., Gomis, R., Frandsen, K.B., Schlienger, J., Dedov, I., Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 24 (2001), 11–15.
43. 43 Ekström, N., Svensson, A., Miftaraj, M., Sundell, K.A., Cederholm, J., Zethelius, B., et al. Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). BMJ Open Diab Res Care, 3, 2015, e000059.
44. 44 Bennett, W.L., Maruthur, N.M., Singh, S., Segal, J.B., Wilson, L., Chatterjee, R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154 (2011), 602–613.
45. 45 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68064989-47ea-4ed5-a20e-43c4ef6ec271#Section_2.4 [accessed 11.10.15].
46. 46 www.accessdata.fda.gov/drugsatfda_docs/label/2012/020741s040lbl.pdf [accessed 11.10.15].
47. 47 Schramm, T.K., Gislason, G.H., Vaag, A., Rasmussen, J.N., Folke, F., Hansen, L.M., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32 (2011), 1900–1908.
48. 48 Dabrowski, M., Wahl, P., Holmes, W.E., Ashcroft, F.M., Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 44 (2001), 747–756.
49. 49 Barnett, D., Craig, J.G., Robinson, D.S., Rogers, M.P., Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol 4 (1977), 455–458.
50. 50 Cheatham, W.W., Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 91 (2010), 262S–266S.
51. 51 Watkins, P.B., Whitcomb, R.W., Hepatic dysfunction associated with troglitazone. N Engl J Med 338 (1998), 916–917.
52. 52 De Fronzo, R.A., Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999), 281–303.
53. 53 Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J.W., Mathisen, A.L., Schneider, R.L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000), 1605–1611.
54. 54 Lebovitz, H.E., Dole, J.F., Patwardhan, R., Rappaport, E.B., Freed, M.I., Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001), 280–288.
55. 55 Bloomgarden, Z.T., Troglitazone: current therapeutic role in type 2 diabetes mellitus. Endocr Pract 4 (1998), 213–218.
56. 56 Fonseca, V., Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115 (2003), 42S–48S.
57. 57 Mudaliar, S., Chang, A.R., Henry, R.R., Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9 (2003), 406–416.
58. 58 Karalliedde, J., Buckingham, R., Starkie, M., Lorand, D., Stewart, M., Viberti, G., Rosiglitazone Fluid Retention Study Group. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17 (2006), 3482–3490.
59. 59 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a [accessed 29.01.16].
60. 60 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc49188a940639150443b4fa4330c [accessed 29.01.16].
61. 61 Nesto, R.W., Bell, D., Bonow, R.O., Fonseca, V., Grundy, S.M., Horton, E.S., et al. AHA/ADA Consensus Statement. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003), 2941–2948.
62. 62 Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
63. 63 Nissen, S.E., Wolski, K., Topol, E.J., Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. J Am Med Assoc 294 (2005), 2581–2586.
64. 64 Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T., Buse, J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
65. 65 Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R.M., Hanefeld, M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
66. 66 Mahaffey, K.W., Hafley, G., Dickerson, S., Burns, S., Tourt-Uhliq, S., White, J., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 166 (2013), 240–249.
67. 67 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm376365.htm [accessed 29.01.16].
68. 68 Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
69. 69 Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. J Am Med Assoc 298 (2007), 1180–1188.
70. 70 Kahn, S.E., Zinman, B., Lachin, J.M., Haffner, S.M., William, H., Herman, W.H., Holman, R.R., et al., For the A Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31 (2008), 845–851.
71. 71 Loke, Y.K., Singh, S., Furberg, C.D., Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180 (2009), 32–39.
72. 72 Colmers, I.N., Bowker, S.L., Majumdar, S.R., Jeffrey, A., Johnson, J.A., Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 184 (2012), E675–E683.
73. 73 Wei, L., MacDonald, T.M., Mackenzie II, Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 75 (2013), 254–259.
74. 74 Holman, R.R., Cull, C.A., Turner, R.C., A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22 (1999), 960–964.
75. 75 Van de Laar, F., Lucassen, P.L., Akkermans, R.P., Van de Lisdonk, E.H., Rutten, G.E., Van Weel, C., Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev, 18, 2005, CD003639.
76. 76 Zhu, Q., Tonq, Y., Wu, T., Li, J., Tong, N., Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther 35 (2013), 880–899.
77. 77 Mertes, G., Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 52 (2001), 193–204.
78. 78 Hoffmann, J., Spengler, M., Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 103 (1997), 483–490.
79. 79 Li, C., Hung, Y.J., Qamruddin, K., Aziz, M.F., Stein, H., Schmidt, B., International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 92 (2011), 57–64.
80. 80 Weng, J., Soegondo, S., Schnell, O., Sheu, W.H.H., Grzeszczak, W., Watada, H., et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes Metab Res Rev 31 (2015), 155–167.
81. 81 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c2db888-775c-4baf-a1b4-1cfa63b83357 [accessed 20.10.15].
82. 82 Zeymer, U., Schwarzmaier-D'assie, A., Petzinna, D., Chiasson, J.L., STOP-NIDDM Trial Research Group. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomized STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 11 (2004), 412–415.
83. 83 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c2db888-775c-4baf-a1b4-1cfa63b83357#LINK_c079fcdf-98e6-422b-8fb4-83da3dc7dd2f [accessed 20.10.15].
84. 84 MCIntyre, N., Holdsworth, C.D., Turner, D.S., New interpretation of oral glucose tolerance. Lancet 2:7349 (1964), 20–21.
85. 85 Kim, W., Egan, J.M., The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60 (2008), 470–512.
86. 86 Koliaki, C., Doupis, J., Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2 (2011), 101–121.
87. 87 Aaboe, K., Knop, F.K., Vilsbøll, T., Deacon, C.F., Holst, J.J., Madsbad, S., et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12 (2010), 323–333.
88. 88 Cernea, S., Raz, I., Therapy in the early stage: incretins. Diabetes Care 34 (2011), S264–S271.
89. 89 Amori, R.E., Lau, J., Pittas, A.G., Efficacy and safety of incretin therapy in type 2 diabetes systematic review and meta-analysis. J Am Med Assoc 298 (2007), 194–206.
90. 90 Karagiannis, T., Paschos, P., Paletas, K., Matthews, D.R., Tsapas, A., Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, 344, 2012, e1369.
91. 91 Valensi, P., de Pouvourville, G., Benard, N., Chanut-Vogel, C., Kempf, C., Eymard, E., et al. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: the ODYSSEE observational study. Diabetes Metab 41 (2015), 231–238.
92. 92 Ku, E.J., Jung, K.Y., Kim, Y.J., Kim, K.M., Moon, J.H., Choi, S.H., et al. Four-year durability of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes in clinical practice; COSMIC Study. PLoS One, 10, 2015, e0129477.
93. 93 Karagiannis, T., Boura, P., Tsapas, A., Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf 5 (2014), 138–146.
94. 94 https://www.gov.uk/drug-safety-update/dipeptidylpeptidase-4-inhibitors-risk-of-acute-pancreatitis [accessed 09.12.15].
95. 95 Faillie, J.L., Azoulay, L., Patenaude, V., Hillaire-Buys, D., Suissa, S., Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ, 348, 2014, g2780.
96. 96 https://www.medicines.org.uk/emc/medicine/20734#POSOLOGY [accessed 04.10.15].
97. 97 http://www.fda.gov/safety/medwatch/safetyinformation/ucm460662.htm [accessed 03.11.15].
98. 98 Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
99. 99 Tricco, A.C., Antony, J., Khan, P.A., Ghassemi, M., Hamid, J.S., Ashoor, H., et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open, 4, 2014, e005752.
100. 100 Ou, S.M., Shih, C.J., Chao, P.W., Chu, H., Kuo, S.C., Lee, Y.J., et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 163 (2015), 663–672.
101. 101 http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm426278.htm [accessed 03.11.15].
102. 102 Gerich, J.E., Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27 (2010), 136–142.
103. 103 Haas, B., Eckstein, N., Pfeifer, V., Mayer, P., Hass, M.D.S., Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes, 4, 2014, e143.
104. 104 Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
105. 105 Liu, X.Y., Zhang, N., Chen, R., Zhao, J.G., Yu, P., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications 29 (2015), 1295–1303.
106. 106 Clar, C., Gill, J.A., Court, R., Waugh, N., Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open, 2, 2012, e001007.
107. 107 Heerspink, H.J.L., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
108. 108 http://www.fda.gov/downloads/drugs/drugsafety/ucm439564.pdf [accessed 30.01.16].
109. 109 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3#section-5.3 [accessed 04.11.15].
110. 110 http://www.fda.gov/drugs/drugsafety/drugsafetypodcasts/default.htm [accessed 03.11.15].
111. 111 Peters, A.L., Buschur, E.O., Buse, J., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
112. 112 Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, Hantel, S., et al., For the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
113. 113 Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of antihyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
114. 114 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 [accessed 30.01.16].
115. 115 Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., Umpierrez, G., Zimmerman, R.S., Bailey, T.S., et al. American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract 21:Suppl. 1 (2015 Apr), 1–87.
116. 116 [No authors listed], United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed noninsulin dependent diabetes followed for three years. BMJ, 310, 1995, 83.
117. 117 Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract 22 (2016), 84–113.
118. 118 Blonde, L., San Juan, Z.T., Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther 29 (2012), 1–13.
119. 119 Cheong, C., Barner, J.C., Lawson, K.A., Johnsrud, M.T., Patient adherence and reimbursement amount for antidiabetic fixed dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 30 (2008), 1893–1907.
120. 120 Blonde, L., San Juan, Z.T., Bolton, P., Fixed-dose combination therapy in type2 diabetes mellitus. Endocr Pract 20 (2014), 1322–1332.